Table 3.
Results of Autologous Hematopoietic Stem Cell Transplant in Pediatric Acute Lymphoblastic Leukemia in CR2 and VHR CR1
| Author (Reference) | N. Pts | Median Age (Years) (Range) | Years | Purging | Conditioning Regimen | Outcome (Years) |
|---|---|---|---|---|---|---|
| Billet (1993)29 | 66 CR1, CR2 | 8 (3–18) | 1980–1990 | MoAbs | ETP+CA+CY+ TBI | EFS 47% (3) |
| Billet (1993)30 | 51 CR2 | 9 (3–18) | 1980–1991 | MoAbs | ETP+CA+CY+TBI | EFS 53% (NR) |
| Messina (1998)32 | 154 CR2; >CR2 | 10 (3–21) | 1984–1994 | ASTA-Z | TBI+CY; BU+CY | EFS-CR2 34.6%; EFS >CR2 10.6% (8) |
| Maldonado (1998)31 | 55 CR2 | 8 (3–17) | 1987–1994 | MoAbs | TBI+CY | EFS 46% (6) |
| Borgmann (1995)33 | 66 CR2 | 6.3 (2–18) | 1983–1994 | MoAbs/ASTA-Z | ETP+TBI±CY/ETP+CY+BU or Thiotepa | EFS 26% (9) |
| Balduzzi (2001–2011)35 | 30 CR2 | 9 (5–16) | 1997–1999 | MoAbs | TBI+CY+ETP | OS 86.5%; EFS 73.3% (5) |
| Houtenbos (2001)36 | 24 CR2; >CR2 | (0->10) | 1990–1996 | VCR+ETP+Verapamil | TBI+verapamil+ETP+CY | OS 54%; DFS 42% (2) |
| Ribera (2007)37 | 38 VHR-CR1 | (1–17) | 1993–2002 | No | TBI+CY; BU+CY | OS 45%; DFS 44% (5) |
| Hong (2018)38 | 10 VHR-CR1 | 4.3 (0.3–10.7) | 1997–2012 | No | BCVAC | OS 70%; EFS 70% (NR) |
| Capria (2018)39 | 28 VHR-CR1; CR2 | 31 (10–68) | 1996–2015 | No | BU+CY/ETP/Thiotepa/MEL | OS 46%; DFS 44% (10) |
Abbreviations: ASTA-Z, maphosphamide; BCVAC, carmustine, etoposide, cytarabine, cyclophosphamide; BU, busulfan; CA, cytarabine; CR1, first complete remission; CR2, second complete remission; CY, cyclophosphamide; DFS, disease-free survival; EFS, event-free survival; ETP, etoposide; MEL, melfalan; MoAbs, monoclonal antibodies; NR, not reported; OS, overall survival; pts, patients; TBI, total body irradiation; VCR, vincristine; VHR, very high risk.